Trial Profile
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Temsirolimus (Primary)
- Indications Adrenocortical carcinoma; Carcinoma; Endometrial cancer; Ewing's sarcoma; Haemangioblastoma; Haemangiosarcoma; Liver cancer; Malignant thymoma; Meningioma; Neuroendocrine tumours; Ovarian cancer; Paraganglioma; Phaeochromocytoma; Thyroid cancer
- Focus Therapeutic Use
- 23 Feb 2024 Planned End Date changed from 30 Jan 2024 to 31 Dec 2024.
- 02 Nov 2023 Planned End Date changed from 30 Sep 2023 to 30 Jan 2024.
- 09 Jan 2023 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.